These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 11693459)

  • 1. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.
    Goodin DS
    Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L; Clerico M
    J Neurol; 2005 Sep; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
    Chofflon M; Ben-Amor AF
    Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
    [No Abstract]   [Full Text] [Related]  

  • 6. History of modern multiple sclerosis therapy.
    Lublin F
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.
    Grigoriadis N
    Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferon beta-1a in relapsing-remitting multiple sclerosis.
    Blumhardt L
    Hosp Med; 1999 Mar; 60(3):192-5. PubMed ID: 10476242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta 1a.
    Pozzilli C; Koudriavtseva T
    Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
    Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
    Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
    Hartung HP
    Expert Opin Pharmacother; 2009 Feb; 10(2):291-309. PubMed ID: 19236200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between disease activity and dose-response relationships with beta interferon therapies in the treatment of multiple sclerosis.
    Jeffery DR
    J Neurol Sci; 2000 Sep; 178(1):2-9. PubMed ID: 11018242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
    Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
    Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
    Clanet M; Kappos L; Hartung HP; Hohlfeld R;
    Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.